Skip to main content

Advertisement

Table 2 Clinical and pathological data of Cohort #2 (prostate biopsies)

From: MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

Patients, n 74
Median age, years (range) 68 (49–85)
Median PSA (ng/mL) (range) 18.22 (4.52-542)
Clinical stage
T2 (%) 48 (64.9)
T3/T4 (%) 26 (35.1)
Gleason score
<7 (%) 30 (40.5)
≥7 (%) 44 (59.5)
Follow up
Median (months) (range) 114.9 (10.3–170.1)
Patients without remission (%) 3 (4)
Biochemical recurrence (%) 29 (39.2)
Death due to PCa (%) 13 (17.6)
Therapy
Surgery (%) 17 (23.0)
ADT (%) 35 (47.3)
Radiotherapy (%) 4 (5.4)
ADT + Radiotherapy (%) 17 (23.0)
Radiotherapy + Criotherapy (%) 1 (1.3)
CAPRA Score
Low-risk (0–2) 7 (9.5)
Intermediate-risk (3–5) 26 (35.1)
High-risk (6–10) 41 (55.4)
  1. ADT- androgen deprivation therapy